Jefferies Group Lowers Hikma Pharmaceuticals (HKMPF) to Underperform

Jefferies Group downgraded shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) from a hold rating to an underperform rating in a report issued on Wednesday morning, MarketBeat.com reports. Jefferies Group also issued estimates for Hikma Pharmaceuticals’ FY2017 earnings at $0.87 EPS, FY2018 earnings at $0.75 EPS, FY2019 earnings at $0.82 EPS, FY2020 earnings at $0.94 EPS, FY2021 earnings at $1.01 EPS and FY2022 earnings at $1.06 EPS.

Separately, Zacks Investment Research upgraded Hikma Pharmaceuticals from a strong sell rating to a hold rating in a research report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. Hikma Pharmaceuticals presently has a consensus rating of Hold.

Shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) traded down $1.04 during trading hours on Wednesday, reaching $14.06. The company’s stock had a trading volume of 600 shares, compared to its average volume of 17. Hikma Pharmaceuticals has a 52-week low of $12.40 and a 52-week high of $27.50.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Lowers Hikma Pharmaceuticals (HKMPF) to Underperform” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/jefferies-group-lowers-hikma-pharmaceuticals-hkmpf-to-underperform.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply